Phaseline

Companies › Wave Life Sciences USA

Wave Life Sciences USA: clinical trials, targets and expected readouts

3 active drug programs in 3 registered trials: 3 Phase 1; Metabolic and endocrine, Neurology; next expected readout Apr 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
WVE-N531
Antisense oligonucleotide (ASO) targeting exon 53 skipping in DMD
DMDPhase 1Duchenne Muscular DystrophyApr 2027
WVE-006
RNA editing oligonucleotide to correct alpha-1 antitrypsin deficiency
SERPINA1Phase 1Alpha-1 Antitrypsin DeficiencySep 2027
WVE-007
Stereopure siRNA oligonucleotide
–Phase 1Overweight and ObesityDec 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT04906460WVE-N531Phase 1Duchenne Muscular DystrophyNeurologyApr 2027
NCT06405633WVE-006Phase 1Alpha-1 Antitrypsin DeficiencyMetabolic and endocrineSep 2027
NCT06842186WVE-007Phase 1Overweight and ObesityMetabolic and endocrineDec 2027

From the company's SEC filings

Cash and short-term investments of $431m on 2026-09-30; operating cash outflow about $233m a year; runway about 22 months at that burn, to Aug 2028

Press releases filed as 8-K in the last year:

Agreements filed with the SEC (item 1.01), last two years

Targets

DMD (1) SERPINA1 (1)

Companies with the same targets

Solid Biosciences NS Pharma Sarepta Therapeutics Dyne Therapeutics Avidity Biosciences REGENXBIO Precision BioSciences Belief BioMed (Beijing) Insmed Gene Therapy Nippon Shinyaku

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.